The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.

FOX 5 spoke exclusively with a participant in a study for a new injectable drug to prevent HIV. Emory University medical ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

Lenacapavir, an injectable drug for HIV prevention, is praised as a potential game-changer and offers hope for those who find daily oral medications challenging. The drug requires administration ...

Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

It is the first time that a PrEP trial has been shown to prevent any HIV infections from slipping through the net, according to Gilead, and showed a subcutaneous injection with lenacapavir every ...

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...